<p>Time course of plasma glucose (top), insulin (middle), and FFAs (bottom) concentrations during euglycemic (approximately 5.5 mM glucose) –hyperinsulinemic (approximately 500 pM insulin) clamps in patients with T2DM (<i>n</i> = 10) (diamonds), age- and BMI-matched controls (CONo; <i>n</i> = 10) (squares), and young healthy controls (CONy; <i>n</i> = 11) (triangles). All units expressed as means ± SD. * <i>p</i> < 0.05 T2DM versus controls.</p
BACKGROUND: Increased glycemic variability is associated with an increase risk of adverse clinical o...
<p>Changes from the basal period in the rates of endogenous glucose production (EGP) and whole-body ...
<p>All data are presented as means±SE or median (range), (n = 7 unless indicated otherwise). T2DSI ...
<p>Values are means ± SE and median (1<sup>st</sup> quartile—3<sup>rd</sup> quartile); Time 0, prior...
<p>Whole body glucose disposal (A), concentration of intramyocellular G-6-P (B), and ifATP (C) durin...
<p>Values are means ± SE and median (1<sup>st</sup> quartile—3<sup>rd</sup> quartile); Time 0, prior...
<p>Rates of endogenous glucose production (EGP) and whole-body glucose disposal (GDR) in the basal p...
<p>A. Plasma glucose and B. glucose infusion rate during hyperinsulinemic-euglycemic clamp (circles ...
OBJECTIVE — We sought to assess the risk of progression to type 2 diabetes in normal glucose toleran...
Background: Increased glycemic variability is associated with an increase risk of adverse clinical o...
<p>All data are presented as means±SE or median (range) (n = 7). T2DSI = type 2 diabetes, severely...
<p>Plasma glucose <b>(A, B)</b>, insulin <b>(C, D)</b> and glucagon <b>(E, F)</b> concentration curv...
Blood glucose levels were not different among groups during the duration of the clamp procedures. Li...
Blood glucose concentrations were not different among groups 45 minutes post 2-deoxyglucose administ...
<p>Blood samples were drawn every 30 min from participants who received 2 standardized meals (breakf...
BACKGROUND: Increased glycemic variability is associated with an increase risk of adverse clinical o...
<p>Changes from the basal period in the rates of endogenous glucose production (EGP) and whole-body ...
<p>All data are presented as means±SE or median (range), (n = 7 unless indicated otherwise). T2DSI ...
<p>Values are means ± SE and median (1<sup>st</sup> quartile—3<sup>rd</sup> quartile); Time 0, prior...
<p>Whole body glucose disposal (A), concentration of intramyocellular G-6-P (B), and ifATP (C) durin...
<p>Values are means ± SE and median (1<sup>st</sup> quartile—3<sup>rd</sup> quartile); Time 0, prior...
<p>Rates of endogenous glucose production (EGP) and whole-body glucose disposal (GDR) in the basal p...
<p>A. Plasma glucose and B. glucose infusion rate during hyperinsulinemic-euglycemic clamp (circles ...
OBJECTIVE — We sought to assess the risk of progression to type 2 diabetes in normal glucose toleran...
Background: Increased glycemic variability is associated with an increase risk of adverse clinical o...
<p>All data are presented as means±SE or median (range) (n = 7). T2DSI = type 2 diabetes, severely...
<p>Plasma glucose <b>(A, B)</b>, insulin <b>(C, D)</b> and glucagon <b>(E, F)</b> concentration curv...
Blood glucose levels were not different among groups during the duration of the clamp procedures. Li...
Blood glucose concentrations were not different among groups 45 minutes post 2-deoxyglucose administ...
<p>Blood samples were drawn every 30 min from participants who received 2 standardized meals (breakf...
BACKGROUND: Increased glycemic variability is associated with an increase risk of adverse clinical o...
<p>Changes from the basal period in the rates of endogenous glucose production (EGP) and whole-body ...
<p>All data are presented as means±SE or median (range), (n = 7 unless indicated otherwise). T2DSI ...